AIMDHIGH SIGNALFINANCIAL10-K

AIMD underwent a dramatic strategic pivot from diversified healthcare to AI-powered "smelltech" while burning through 89% of its cash reserves and suffering a 51% decline in stockholder equity.

The company has fundamentally repositioned itself from VELDONA therapeutics and point-of-care testing to commercializing an "AI Nose" scent digitization platform, representing a complete business model transformation. The severe cash burn from $3.9M to $417K combined with massive equity destruction raises immediate liquidity and going concern questions for this pivot strategy.

Comparing 2026-03-30 vs 2025-03-07View on EDGAR →
FINANCIAL ANALYSIS

Despite revenue growing 499% to $124K and achieving positive gross profit of $103K, AIMD's financial position deteriorated severely with an 89% cash decline to just $417K and stockholder equity falling 51% to $7.6M. The company doubled its inventory investment while interest expense surged 169%, suggesting increased debt financing needs amid the cash burn. The dramatic revenue improvement appears insufficient to offset the substantial capital consumption required for this strategic transformation.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+499%
$21K→$124K

Strong top-line growth of 499% — accelerating demand or successful expansion into new markets.

Gross Profit
P&L
+422.9%
-$32K→$103K

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Interest Expense
P&L
+169.4%
$54K→$144K

Interest expense surged 169.4% — significant debt increase or rising rates materially impacting earnings.

Inventory
Balance Sheet
+105.6%
$144K→$296K

Inventory surged 105.6% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Cash & Equivalents
Balance Sheet
-89.3%
$3.9M→$417K

Cash declined 89.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-73.7%
$4.3M→$1.1M

Current assets declined 73.7% — monitor working capital adequacy and short-term liquidity.

Current Liabilities
Balance Sheet
-72.7%
$4.0M→$1.1M

Current liabilities reduced — improved short-term financial position and working capital health.

Capital Expenditure
Cash Flow
+62%
$21K→$35K

Capital expenditure jumped 62% — major investment cycle underway; assess returns on deployment.

Accounts Receivable
Balance Sheet
-60.7%
56→22

Receivables declined — improved collection efficiency or conservative revenue recognition.

Stockholders Equity
Balance Sheet
-51.3%
$15.5M→$7.6M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-07
ADDED
As of March 30, 2026, there were issued and outstanding 7,266,011 shares of the registrant s common stock, par value $ 0.01 , which is the only class of common or voting stock of the registrant.
(the Company ), incorporated in the State of Texas in 1984, is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics.
Our primary strategic focus is the commercialization of our proprietary scent digitization platform, AI Nose, while we also continue to develop therapeutic assets based on our low-dose oral interferon program, VELDONA .
Our core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which we refer to as a smell language model ( SLM ), to digitize scent and volatile organic compound ( VOC ) signals into Smell ID, a machine-readable data format.
AI Nose is initially developed in healthcare-related settings, including point-of-care testing ( POCT ).
+7 more — sign up free →
REMOVED
As of June 30, 2024, the aggregate market value of the shares of common stock outstanding, other than shares held by persons who may be deemed affiliates of the Registrant, computed by reference to the closing price of $ 0.8136 for the Registrant s common stock on June 30, 2024, as reported on Nasdaq Capital Market, was approximately $ 3,350,118 .
(the Company ), incorporated in the State of Texas in 1984, is a diversified healthcare company focused on the development of novel point-of-care testing (the POCT ), therapeutics based on very low-dose interferon alpha (the VELDONA ), and synthetic RNA-driven preventative medicine.
Our product pipeline includes commercial-stage VELDONA Pet supplements, clinical-stage VELDONA human therapeutics and telehealth-friendly POCTs powered by the AI Nose technology platform.
Our vision for AI Nose is to digitize smell, extend application beyond healthcare, and ultimately become AI s nose.
We have historically involved in the research and development of therapeutics based on VELDONA.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →